A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 23 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-06.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 56th largest by enrollment, is one of 5 that started in 2006, is one of 29 in phase 4, and was the 10th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
By country, each count listing its studies:
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 12 · Phase 4 29
First in 2002; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 59 interventional studies. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 31st largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2006, is one of 16 in phase 4, and was the 6th registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing peginterferon alfa-2a in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the efficacy and safety of PEGASYS in patients with chronic hepatitis B who are either treatment-naive, or who have failed lamivudine- or interferon-treatment in the past. All patients will receive PEGASYS, 180 micrograms s.c. weekly for 48 weeks, followed by 48 weeks of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: peginterferon alfa-2a [Pegasys]
180 micrograms sc weekly for 48 weeks
Number of HBeAg Positive Participants With Hepatitis B Virus Deoxyribonucleic Acid <100,000 Copies Per mL
This study included four Hepatitis B Early Antigen (HBeAg) positive participants. Participants with Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) \<100,000 copies/mL were reported.
Time frame: Week 96
Number of HBeAg Negative Participants With HBV DNA < 20,000 Copies Per mL
This study included 14 HBeAg negative participants. Participants with HBV DNA \<20,000 copies/mL were reported.
Time frame: Week 96
Number of HBeAg Positive Participants With HBV DNA <400 Copies Per mL, HBsAg Seroconversion, Normalization of ALT, and Sustained HBe Seroconversion
Hepatitis B Surface Antigen (HBsAg) seroconversion is defined as a decrease in HBsAg to undetectable levels and a gain of detectable levels of Hepatitis B surface antibody (HBsAb). Sustained HBe seroconversion is defined as loss of HBeAg and presence of hepatitis B e-antibody (HBeAb). This study included 4 HBeAg positive participants.
Time frame: Week 96
Number of HBeAg Negative Participants With HBV DNA <400 Copies/mL, HbsAg Seroconversion and Normalization of ALT
Hepatitis B Surface Antigen (HBsAg) seroconversion is defined as a decrease in HBsAg to undetectable levels and a gain of detectable levels of HBsAb. This study included 14 HBeAg negative participants.
Time frame: Week 96
Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)
All participants who received at least one dose of the study drug were analysed. Number of participants with any adverse events and any serious adverse events are reported.
Time frame: Up to Week 96
Mean Change in Laboratory Parameters (ALT Levels)
Mean Change in Laboratory parameters (ALT levels) is reported.
Time frame: From Screening (Day 0) to Week 96
The study was conducted at 7 centers in Russia.
| Milestone | Peginterferon Alfa-2a |
|---|---|
| Started | 18 |
| Completed | 7 |
| Not completed | 11 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 9 |
| Withdrew: Lack of efficacy | 1 |
This study included four Hepatitis B Early Antigen (HBeAg) positive participants. Participants with Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) \<100,000 copies/mL were reported.
| Participants | Peginterferon Alfa-2a |
|---|---|
| Number of HBeAg Positive Participants With Hepatitis B Virus Deoxyribonucleic Acid <100,000 Copies Per mL | 4 |
This study included 14 HBeAg negative participants. Participants with HBV DNA \<20,000 copies/mL were reported.
| Participants | Peginterferon Alfa-2a |
|---|---|
| Number of HBeAg Negative Participants With HBV DNA < 20,000 Copies Per mL | 3 |
Hepatitis B Surface Antigen (HBsAg) seroconversion is defined as a decrease in HBsAg to undetectable levels and a gain of detectable levels of Hepatitis B surface antibody (HBsAb). Sustained HBe seroconversion is defined as loss of HBeAg and presence of hepatitis B e-antibody (HBeAb). This study included 4 HBeAg positive participants.
| Participants | Peginterferon Alfa-2a |
|---|---|
| HBV DNA <400 copies/mL | 4 |
| HBsAg seroconversion | 0 |
| ALT normalization | 4 |
| Sustained HBe seroconversion | 4 |
Hepatitis B Surface Antigen (HBsAg) seroconversion is defined as a decrease in HBsAg to undetectable levels and a gain of detectable levels of HBsAb. This study included 14 HBeAg negative participants.
| Participants | Peginterferon Alfa-2a |
|---|---|
| HBV DNA <400 copies/mL | 3 |
| HBsAg seroconversion | 2 |
| ALT normalization | 3 |
All participants who received at least one dose of the study drug were analysed. Number of participants with any adverse events and any serious adverse events are reported.
| Participants | Peginterferon Alfa-2a |
|---|---|
| Any AEs | 3 |
| Any SAEs | 0 |
Mean Change in Laboratory parameters (ALT levels) is reported.
| International units per liter (IU/L) | Peginterferon Alfa-2a |
|---|---|
| ALT (Week 1) | 92.9 ± 73.2 |
| ALT (Week 2) | 97.2 ± 89.9 |
| ALT (Week 4) | 109.4 ± 133.6 |
| ALT (Week 8) | 81.2 ± 105.4 |
| ALT Week 12) | 65.1 ± 35.9 |
| ALT (Week 18) | 53.3 ± 26.2 |
| ALT (Week 24) | 66.2 ± 32.3 |
| ALT (Week 32) | 55 ± 30.2 |
| ALT (Week 40) | 46 ± 17.6 |
| ALT (Week 48) | 38.4 ± 18.4 |
| ALT (Week 52) | 37.1 ± 5.1 |
| ALT (Week 60) | 40.5 ± 15.1 |
| ALT (Week 72) | 36.9 ± 4.5 |
| ALT (Week 96) | 32.8 ± 8.1 |
Collected over Up to Week 96. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Peginterferon Alfa-2a | — | 0/18 (0%) | 3/18 (16.7%) |
| Event | Peginterferon Alfa-2a |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/18 |
| DepressionPsychiatric disorders | 1/18 |
All participants who received at least one dose of the study drug were included.
| Age, Categorical(Participants) | Peginterferon Alfa-2a |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 18 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Peginterferon Alfa-2a |
|---|---|
| Female | 4 |
| Male | 14 |
| Hepatitis B Early Antigen (HBeAg) positive participants(participants) | Peginterferon Alfa-2a |
|---|---|
| Number | 4 |
| HBeAg-negative participants(Participants) | Peginterferon Alfa-2a |
|---|---|
| Count of participants | 14 |
The record gives a start of Aug 2006, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 7 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a